Dr. Brott came to UAB in November, 2000 as an Assistant Professor of Medicine in the Division of Cardiovascular Disease. She obtained a Bachelor of Science in Materials Science and Engineering from the Massachusetts Institute of Technology. She then completed her medical degree at Loyola University, Stritch School of Medicine in Maywood, IL in 1988 and completed an Internal Medicine residency (1991) at Beth Israel Medical Center – Harvard Medical School in Boston, MA. Dr. Brott completed both a General Cardiology fellowship (1994) and an Interventional Cardiology fellowship (1995) at Duke University, Durham, NC. Afterwards, she was hired on with Vanderbilt University and stayed there for four years before joining us the Division of Cardiovascular Disease at UAB.
Dr. Brott is an active member of the Interventional Cardiology section, and serves as the Director of the Interventional Cardiology Fellowship Program.
Dr. Brott serves on the editorial boards of the Journal of the American College of Cardiology and JACC: Cardiovascular Interventions, and is a reviewer of numerous journals. Dr. Brott serves on several councils and grant review committees including the American Heart Association Council on Clinical Cardiology (2004 – present), NIH BMBI Study Section (Biomaterials and Biointerfaces) (2009 – 2016), NIH SBIB Study Section (Surgical Sciences, Biomedical Imaging, and Bioengineering) (2013 – present), and the NIH Special Emphasis Panel - Biomedical Imaging and Engineering Area Review.
Dr. Brigitta Brott’s research interests are the understanding of endovascular device – artery interactions and the improvement of vascular compatibility of stents and other implants. She also focuses on the treatment of patients with congestive heart failure using local delivery of novel cell therapies. Her focus is on the development and evaluation of new interventional device coatings, in order to improve patient outcomes. In this role, she has co-founded Endomimetics, LLC, a UAB spin-off company, which develops coatings to improve healing and inhibit abnormal clotting on implants.